http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2680139-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d584042a524740a406723fe1631e49e5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2018-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_555c4737962a4344fbe5abae9dffac4e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_725872ba9e461b743e571a80596223b3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82cb076a5d845a27c161818c04855081 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62d22ac76dc0bcac0e978f00f093ec39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71c0d34f81cec5cafa515048160d3d54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d5f8abfd1e28aaf5e9308333812c4fb |
| publicationDate | 2019-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2680139-C1 |
| titleOfInvention | Method for predicting development of cardiotoxicity in patients with breast cancer within 12 months after chemotherapy with antracyclic drugs |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine and can be used in cardiology, angiology, cardiac surgery, oncology, therapy, and rehabilitation. Problem is solved by determining the soluble Fas-ligand in the serum by means of the ELISA method. If there is a level of soluble Fas-ligand of more than 95.8 pg/ml in patients with breast cancer after chemotherapy with anthracyclines, a high risk of cardiotoxicity is predicted during the next 12 months of follow-up. Proposed method allows to predict a high risk of cardiotoxicity after 12 months of observation after chemotherapy with anthracyclines, due to the death of myocardial cells (necrosis, apoptosis), cardiac remodeling and progressive heart failure, by determining serum activator of Fas-mediated apoptosis – soluble Fas ligand (sFas-L), that allows to select a priority group of patients with an increased risk of cardiovascular complications for follow-up observation with the organization of effective targeted measures aimed at preventing the development of cardiotoxicity. n EFFECT: development of an objective, highly informative method for predicting cardiotoxicity after chemotherapy with anthracycline drugs in patients with breast cancer based on soluble Fas ligand (sFas-L) in the blood. n 1 cl, 2 ex, 3 tbl, 1 dwg |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2744682-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2793672-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2787925-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2741371-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2714683-C1 |
| priorityDate | 2018-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.